Alembic Pharmaceuticals Full Year 2025 Earnings: Beats Expectations

Simply Wall St · 06/19 00:06

Alembic Pharmaceuticals (NSE:APLLTD) Full Year 2025 Results

Key Financial Results

  • Revenue: ₹66.7b (up 7.1% from FY 2024).
  • Net income: ₹5.83b (down 5.3% from FY 2024).
  • Profit margin: 8.7% (down from 9.9% in FY 2024). The decrease in margin was driven by higher expenses.
  • EPS: ₹29.68 (down from ₹31.33 in FY 2024).

APLLTD Post-Clinical Trial Products

  • Pre-registration: 72.
  • Approved (during full year): 56.
  • Launched (during full year): 51.
earnings-and-revenue-growth
NSEI:APLLTD Earnings and Revenue Growth June 19th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Portfolio Valuation calculation on simply wall st

Alembic Pharmaceuticals Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) also surpassed analyst estimates by 3.8%.

Looking ahead, revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India.

Performance of the Indian Pharmaceuticals industry.

The company's shares are down 3.8% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 1 warning sign for Alembic Pharmaceuticals you should be aware of.